← Leaderboards
Andres Forero
University Of Alabama At Birmingham
$2,840,204
Attributed
$3,796,683
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $697.8K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,796,683 · 11
By mechanism
P30$1,906,876 · 2
U10$1,195,599 · 1
R21$566,608 · 1
M01$127,600 · 7
Top collaborators
- Ronald D. Alvarez3 shared
- Jennifer De Los Santos3 shared
- Paolo Erba3 shared
- Carla I Falkson3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Charles A. Leath$2,454,862
- Amitkumar N Mehta$1,687,160
- Donald J Buchsbaum$5,699,601
- Erica Michelle Stringer-Reasor$677,773
- Jennifer De Los Santos$438,240
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelClinical ResearchGrantMalignant NeoplasmsAlabamaComprehensive Cancer CenterClinical TrialsFacultyNational Cancer InstituteInstitutesWorking GroupCancer CenterIndustryMeetingsInstitutionFundingCancer PatientEnrollmentBasic ScienceLeadMalignant Neoplasm Of BrainInvestigator-Initiated TrialMalignant Neoplasm Of PancreasEnsure
Grant awards (33)
Clinical Protocol and Data Management$347,960
P30 · FY2019 · CA · contact PI
03 Experimental Therapeutics Program$116,178
P30 · FY2019 · CA · contact PI
03 Experimental Therapeutics Program$8,695
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$8,695
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$334,236
P30 · FY2018 · CA · contact PI
03 Experimental Therapeutics Program$96,773
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$8,650
P30 · FY2018 · CA · contact PI
03 Experimental Therapeutics Program$8,649
P30 · FY2018 · CA · contact PI
03 Experimental Therapeutics Program$3,965
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$3,965
P30 · FY2018 · CA · contact PI
03 Experimental Therapeutics Program$2,264
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,264
P30 · FY2018 · CA · contact PI
03 Experimental Therapeutics Program$1,978
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$1,978
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$371,802
P30 · FY2017 · CA · contact PI
03 Experimental Therapeutics Program$107,953
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$435,026
P30 · FY2016 · CA · contact PI
03 Experimental Therapeutics Program$28,454
P30 · FY2016 · CA · contact PI
Clinical Protocol and Data Management$8,696
P30 · FY2016 · CA · contact PI
03 Experimental Therapeutics Program$8,695
P30 · FY2016 · CA · contact PI
NCTN Deep South Research Consortium$497,800
U10 · FY2015 · CA
NCTN Deep South Research Consortium$199,999
U10 · FY2015 · CA
NCTN Deep South Research Consortium$497,800
U10 · FY2014 · CA
UAB 0540 - PHASE I STUDY OF CS-1008 FOR PATIENTS WITH ADVANCED TUMOR OR LYMPHOMA$67,814
M01 · FY2007 · RR · contact PI
UAB 0467 PHASE II TRIAL OF LETROZOLE WITH BEVACIZUMAB IN WOMEN WITH BREAST CANCE$22,420
M01 · FY2007 · RR · contact PI
UAB 0461 BEVACIZUMAB TO REVERSE ACQUIRED ESTROGEN INDEPENDENCE IN BREAST CANCER$8,580
M01 · FY2007 · RR · contact PI
UAB 0543 - PHASE 2 TRIAL OF C225 -/+ CARBOPLATIN IN TRIPLE NEGATIVE METASTATIC$1,661
M01 · FY2007 · RR · contact PI
Radioimmunotherapy: An Anti-Neoplastic Strategy$280,233
R21 · FY2006 · CA · contact PI
UAB 0472 - STUDY OF 90Y-LABELED IDEC-159$18,095
M01 · FY2006 · RR · contact PI
UAB 0467 PHASE II TRIAL OF LETROZOLE WITH BEVACIZUMAB IN WOMEN WITH BREAST CANCE$7,755
M01 · FY2006 · RR · contact PI
Radioimmunotherapy: An Anti-Neoplastic Strategy$286,375
R21 · FY2005 · CA
90Y-ZEVALIN$999
M01 · FY2005 · RR
Zevalin Radioimmunotherapy Using a Modified Treatment$276
M01 · FY2004 · RR